Kairos Pharma, Ltd.
KAPA · AMEX
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Assets | – | – | – | – |
| Cash & Equivalents | $5,575 | $3,034 | $3,616 | $1,272 |
| Short-Term Investments | $0 | $0 | $0 | $0 |
| Receivables | $0 | $0 | $0 | $0 |
| Inventory | $0 | $0 | $0 | $0 |
| Other Curr. Assets | $1,081 | $1,805 | $2,434 | $2,897 |
| Total Curr. Assets | $6,656 | $4,839 | $6,050 | $4,169 |
| Property Plant & Equip (Net) | $0 | $0 | $0 | $0 |
| Goodwill | $0 | $0 | $0 | $0 |
| Intangibles | $102 | $142 | $182 | $222 |
| Long-Term Investments | $0 | $0 | $0 | $0 |
| Tax Assets | $0 | $0 | $0 | $448 |
| Other NC Assets | $1,308 | $1,692 | $1,705 | $1,377 |
| Total NC Assets | $1,410 | $1,834 | $1,887 | $2,047 |
| Other Assets | $0 | $0 | $0 | $0 |
| Total Assets | $8,066 | $6,673 | $7,937 | $6,216 |
| Liabilities | – | – | – | – |
| Payables | $0 | $676 | $805 | $0 |
| Short-Term Debt | $0 | $0 | $0 | $0 |
| Tax Payable | $0 | $0 | $0 | $0 |
| Deferred Revenue | $0 | $0 | $0 | $0 |
| Other Curr. Liab. | $402 | $0 | $0 | $992 |
| Total Curr. Liab. | $402 | $676 | $805 | $992 |
| LT Debt | $0 | $0 | $0 | $0 |
| Deferred Rev, NC | $0 | $0 | $0 | $0 |
| Deferred Tax Liab, NC | $0 | $0 | $0 | $448 |
| Other NC Liab. | $0 | $0 | $0 | $0 |
| Total NC Liab. | $0 | $0 | $0 | $448 |
| Other Liabilities | $0 | $0 | $0 | $0 |
| Cap. Leases | $0 | $0 | $0 | $0 |
| Total Liabilities | $402 | $676 | $805 | $1,440 |
| Equity | – | – | – | – |
| Pref Stock | $0 | $0 | $0 | $0 |
| Common Stock | $21 | $18 | $16 | $14 |
| Retained Earnings | -$12,897 | -$11,499 | -$10,077 | -$8,815 |
| AOCI | $0 | $0 | $484 | $0 |
| Other Equity | $20,540 | $17,478 | $16,709 | $13,577 |
| Total Equity | $7,664 | $5,997 | $7,132 | $4,776 |
| Supplemental Information | – | – | – | – |
| Minority Interest | $0 | $0 | $0 | $0 |
| Total Liab. & Tot. Equity | $8,066 | $6,673 | $7,937 | $6,216 |
| Net Debt | -$5,575 | -$3,034 | -$3,616 | -$1,272 |